RNA Blockade to Treat Triple Negative Breast Cancer
(PHILADELPHIA, 14June 2019): The US National Cancer Institute has awarded Bound Therapeutics LLC a Small Business Technology Transfer grant starting 15 June for $300,000 to develop “microRNA-21 Blockade of Triple Negative Breast Cancer.” “Triple negative breast cancer strikes younger women, tragically killing half the patients within 4 years,” said Dr. Yuan-Yuan Jin, Chief Operating Officer […]
Bound Therapeutics is selected as a finalist in the UC Science Center QED proof-of-concept program
Twelve experimental technologies under development at nine academic institutions in Pennsylvania, New Jersey and Delaware were named finalists Monday for the University City Science Center’s QED Program. The QED program, established in 2009, is designed to bridge the gap between academic research and product commercialization. Through the program, the Science Center works with 21 academic […]
Bound Therapeutics formed strategic alliance with Bio-Synthesis, Inc. to jointly develop bridged nucleic acid (BNA)-based RNA therapeutics
Bound Therapeutics is featured in Genetic Engineering & Biotechnology News
Why Blocking microRNAs in Triple Negative Breast Cancer Is so Difficult While a triple negative score is hardly ever a good thing, for breast cancer it is especially troubling. Triple-negative breast cancer (TNBC) refers to a disease scenario where the cancer cells do not express the genes for estrogen, progesterone, or HER2/neu receptors simultaneously—making this […]